User menu

Drug discovery in renal disease—towards a more efficient framework

Bibliographic reference Miyata, Toshio ; Ando, Tsuyoshi ; Hiragi, Hisami ; Watanabe, Kanako ; Yamamoto, Fumi ; et. al. Drug discovery in renal disease—towards a more efficient framework. In: Nature Reviews Nephrology, Vol. 10, no. 5, p. 290-296 (2014)
Permanent URL http://hdl.handle.net/2078.1/142004
  1. Ashburn Ted T., Thor Karl B., Drug repositioning: identifying and developing new uses for existing drugs, 10.1038/nrd1468
  2. Levey A.S., Atkins R., Coresh J., Cohen E.P., Collins A.J., Eckardt K.-U., Nahas M.E., Jaber B.L., Jadoul M., Levin A., Powe N.R., Rossert J., Wheeler D.C., Lameire N., Eknoyan G., Chronic kidney disease as a global public health problem: Approaches and initiatives – a position statement from Kidney Disease Improving Global Outcomes, 10.1038/sj.ki.5002343
  3. Shelton Luke M., Kevin Park B., Copple Ian M., Role of Nrf2 in protection against acute kidney injury, 10.1038/ki.2013.248
  4. de Zeeuw Dick, Akizawa Tadao, Audhya Paul, Bakris George L., Chin Melanie, Christ-Schmidt Heidi, Goldsberry Angie, Houser Mark, Krauth Melissa, Lambers Heerspink Hiddo J., McMurray John J., Meyer Colin J., Parving Hans-Henrik, Remuzzi Giuseppe, Toto Robert D., Vaziri Nosratola D., Wanner Christoph, Wittes Janet, Wrolstad Danielle, Chertow Glenn M., Bardoxolone Methyl in Type 2 Diabetes and Stage 4 Chronic Kidney Disease, 10.1056/nejmoa1306033
  5. Zoja C., Corna D., Nava V., Locatelli M., Abbate M., Gaspari F., Carrara F., Sangalli F., Remuzzi G., Benigni A., Analogs of bardoxolone methyl worsen diabetic nephropathy in rats with additional adverse effects, 10.1152/ajprenal.00376.2012
  6. Rossing Peter, Diabetic nephropathy: Could problems with bardoxolone methyl have been predicted?, 10.1038/nrneph.2013.13
  7. Reichert Janice M., A guide to drug discovery: Trends in development and approval times for new therapeutics in the United States, 10.1038/nrd1178
  8. Kola Ismail, Landis John, Opinion: Can the pharmaceutical industry reduce attrition rates?, 10.1038/nrd1470
  9. Boyd R A, Lalonde R L, Nontraditional approaches to first-in-human studies to increase efficiency of drug development: will microdose studies make a significant impact?, 10.1038/sj.clpt.6100058
  10. Ha Hunjoo, Oh Eun Y., Lee Hi B., The role of plasminogen activator inhibitor 1 in renal and cardiovascular diseases, 10.1038/nrneph.2009.15
  11. Izuhara Y., Takahashi S., Nangaku M., Takizawa S., Ishida H., Kurokawa K., van Ypersele de Strihou C., Hirayama N., Miyata T., Inhibition of Plasminogen Activator Inhibitor-1: Its Mechanism and Effectiveness on Coagulation and Fibrosis, 10.1161/atvbaha.107.157479
  12. Izuhara Yuko, Yamaoka Nagahisa, Kodama Hidehiko, Dan Takashi, Takizawa Shunya, Hirayama Noriaki, Meguro Kanji, van Ypersele de Strihou Charles, Miyata Toshio, A Novel Inhibitor of Plasminogen Activator Inhibitor-1 Provides Antithrombotic Benefits Devoid of Bleeding Effect in Nonhuman Primates, 10.1038/jcbfm.2009.272
  13. Tashiro Y., Nishida C., Sato-Kusubata K., Ohki-Koizumi M., Ishihara M., Sato A., Gritli I., Komiyama H., Sato Y., Dan T., Miyata T., Okumura K., Tomiki Y., Sakamoto K., Nakauchi H., Heissig B., Hattori K., Inhibition of PAI-1 induces neutrophil-driven neoangiogenesis and promotes tissue regeneration via production of angiocrine factors in mice, 10.1182/blood-2011-12-399659
  14. Boe A. E., Eren M., Murphy S. B., Kamide C. E., Ichimura A., Terry D., McAnally D., Smith L. H., Miyata T., Vaughan D. E., Plasminogen Activator Inhibitor-1 Antagonist TM5441 Attenuates N -Nitro-L-Arginine Methyl Ester-Induced Hypertension and Vascular Senescence, 10.1161/circulationaha.113.003192
  15. Huang Wen-Tan, Vayalil Praveen K., Miyata Toshio, Hagood James, Liu Rui-Ming, Therapeutic Value of Small Molecule Inhibitor to Plasminogen Activator Inhibitor–1 for Lung Fibrosis, 10.1165/rcmb.2011-0139oc
  16. Ichimura A., Matsumoto S., Suzuki S., Dan T., Yamaki S., Sato Y., Kiyomoto H., Ishii N., Okada K., Matsuo O., Hou F.-F., Vaughan D. E., van Ypersele de Strihou C., Miyata T., A Small Molecule Inhibitor to Plasminogen Activator Inhibitor 1 Inhibits Macrophage Migration, 10.1161/atvbaha.113.301224
  17. Robinson H. M., Pac. Health Dialog., 18, 179 (2012)
  18. Braun M. M., Nat. Rev. Drug Discov., 9, 519 (2010)
  19. Chakma Justin, Chakma Hiroshi, Developing countries can contribute to global health innovation, 10.1038/nm.3086
  20. Lameire Norbert, Van Biesen Wim, Epidemiology of peritoneal dialysis: a story of believers and nonbelievers, 10.1038/nrneph.2009.210
  21. Li P. K., Perit. Dial. Int., 27, S59 (2007)
  22. Prentice Ross L., Surrogate endpoints in clinical trials: Definition and operational criteria, 10.1002/sim.4780080407
  23. Lambers Heerspink Hiddo J., Weldegiorgis Misghina, Inker Lesley A., Gansevoort Ron, Parving Hans-Henrik, Dwyer Jamie P., Mondal Hasi, Coresh Josef, Greene Tom, Levey Andrew S., de Zeeuw Dick, Estimated GFR Decline as a Surrogate End Point for Kidney Failure: A Post Hoc Analysis From the Reduction of End Points in Non–Insulin-Dependent Diabetes With the Angiotensin II Antagonist Losartan (RENAAL) Study and Irbesartan Diabetic Nephropathy Trial (IDNT), 10.1053/j.ajkd.2013.09.016
  24. Burris H. A., J. Clin. Oncol., 15, 2403 (1997)
  25. Asahina Yasuko, Tanaka Ayumi, Uyama Yoshiaki, Kuramochi Kenji, Maruyama Hiroshi, The Roles of Regulatory Science Research in Drug Development at the Pharmaceuticals and Medical Devices Agency of Japan, 10.1177/2168479012469950
  26. Fuchs Tobias Christian, Hewitt Philip, Biomarkers for Drug-Induced Renal Damage and Nephrotoxicity—An Overview for Applied Toxicology, 10.1208/s12248-011-9301-x
  27. Vaidya V. S., Urinary kidney injury molecule-1: a sensitive quantitative biomarker for early detection of kidney tubular injury, 10.1152/ajprenal.00291.2005
  28. Donovan Kieron L., Coles Gerald A., Williams John D., An ELISA for the detection of type IV collagen in human urine—Application to patients with glomerulonephritis, 10.1038/ki.1994.415
  29. Dieterle Frank, Sistare Frank, Goodsaid Federico, Papaluca Marisa, Ozer Josef S, Webb Craig P, Baer William, Senagore Anthony, Schipper Matthew J, Vonderscher Jacky, Sultana Stefan, Gerhold David L, Phillips Jonathan A, Maurer Gérard, Carl Kevin, Laurie David, Harpur Ernie, Sonee Manisha, Ennulat Daniela, Holder Dan, Andrews-Cleavenger Dina, Gu Yi-Zhong, Thompson Karol L, Goering Peter L, Vidal Jean-Marc, Abadie Eric, Maciulaitis Romaldas, Jacobson-Kram David, Defelice Albert F, Hausner Elizabeth A, Blank Melanie, Thompson Aliza, Harlow Patricia, Throckmorton Douglas, Xiao Shen, Xu Nancy, Taylor William, Vamvakas Spiros, Flamion Bruno, Lima Beatriz Silva, Kasper Peter, Pasanen Markku, Prasad Krishna, Troth Sean, Bounous Denise, Robinson-Gravatt Denise, Betton Graham, Davis Myrtle A, Akunda Jackie, McDuffie James Eric, Suter Laura, Obert Leslie, Guffroy Magalie, Pinches Mark, Jayadev Supriya, Blomme Eric A, Beushausen Sven A, Barlow Valérie G, Collins Nathaniel, Waring Jeff, Honor David, Snook Sandra, Lee Jinhe, Rossi Phil, Walker Elizabeth, Mattes William, Renal biomarker qualification submission: a dialog between the FDA-EMEA and Predictive Safety Testing Consortium, 10.1038/nbt.1625
  30. Hoffman John M., Gambhir Sanjiv S., Kelloff Gary J., Regulatory and Reimbursement Challenges for Molecular Imaging, 10.1148/radiol.2453060737
  31. Prasad P. V., Edelman R. R., Epstein F. H., Noninvasive Evaluation of Intrarenal Oxygenation With BOLD MRI, 10.1161/01.cir.94.12.3271
  32. Takasawa M., J. Cereb. Blood Flow Metab., 27, 679 (2007)
  33. Kaneta Tomohiro, Takai Yoshihiro, Iwata Ren, Hakamatsuka Takashi, Yasuda Hiroyasu, Nakayama Katsutoshi, Ishikawa Yoichi, Watanuki Shoichi, Furumoto Shozo, Funaki Yoshihito, Nakata Eiko, Jingu Keiichi, Tsujitani Michihiko, Ito Masatoshi, Fukuda Hiroshi, Takahashi Shoki, Yamada Shogo, Initial evaluation of dynamic human imaging using18F-FRP170 as a new PET tracer for imaging hypoxia, 10.1007/bf03033987
  34. Kaneta T., J. Nucl. Med., 43, 109 (2002)
  35. Rosenberger C., Khamaisi M., Abassi Z., Shilo V., Weksler-Zangen S., Goldfarb M., Shina A., Zibertrest F., Eckardt K.-U., Rosen S., Heyman S.N., Adaptation to hypoxia in the diabetic rat kidney, 10.1038/sj.ki.5002567
  36. Izuhara Y., Renoprotective Properties of Angiotensin Receptor Blockers beyond Blood Pressure Lowering, 10.1681/asn.2005050522
  37. Hajduk Philip J., Greer Jonathan, A decade of fragment-based drug design: strategic advances and lessons learned, 10.1038/nrd2220
  38. Meagher Kristin L., Carlson Heather A., Incorporating Protein Flexibility in Structure-Based Drug Discovery:  Using HIV-1 Protease as a Test Case, 10.1021/ja0469378
  39. Chessari Gianni, Woodhead Andrew J., From fragment to clinical candidate—a historical perspective, 10.1016/j.drudis.2009.04.007
  40. Nangaku M., Izuhara Y., Takizawa S., Yamashita T., Fujii-Kuriyama Y., Ohneda O., Yamamoto M., van Ypersele de Strihou C., Hirayama N., Miyata T., A Novel Class of Prolyl Hydroxylase Inhibitors Induces Angiogenesis and Exerts Organ Protection Against Ischemia, 10.1161/atvbaha.107.148551
  41. Ekins S, Mestres J, Testa B, In silicopharmacology for drug discovery: applications to targets and beyond, 10.1038/sj.bjp.0707306